June 7th 2025
The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.
ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy
FDA Action on MSK Tumor Profiling Assay Breaks Ground on Multiple Fronts
Dr Amy Abernethy on Improving Patient Access to Oncology Clinical Trials